Method of treating inflammation
The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
1. A method of treating systemic, regional, or local inflammation in a patient, said method comprising administration of a therapeutically effective dose of a sorbent for an inflammatory mediator in said patient; wherein the sorbent is a biocompatible polymer;
the biocompatible polymer comprising residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof,
the biocompatible polymer having a pore structure such that the total pore volume of pore size in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer; wherein the ratio of pore volume between 50 Å to 3,000 Å (pore diameter) to the pore volume between 500 Å to 3,000 Å (pore diameter) of the polymer is smaller than 200:1; or the ratio of pore volume between 50 Å to 3,000 Å in diameter to the pore volume between 1,000 Å to 3,000 Å in diameter of the polymer is greater than 20:1,
said sorbent being administered orally, via a feeding tube, peritoneally, or rectally;
wherein said inflammatory mediator is a cytokine produced in response to an infection in said patient chosen from endotoxemia, Bacillus anthracis (anthrax), influenza virus, smallpox virus, Yersinia pestis (plague), Ebola virus, Marburg virus, Francisella tularensis (tularemia), hantavirus, cholera toxin, botulinum toxin, ricin toxin, Salmonella, Escherichia coli, Shigella , or Listeria.
2. The method of claim 1 , wherein the biocompatible polymer comprises cross-linked, porous styrene or divinylbenzene copolymer.
3. The method of claim 1 , wherein said inflammatory mediator is present in physiological fluid or a carrier fluid in the patient.
4. The method of claim 3 , wherein said physiological fluids is nasopharyngeal, oral, esophageal, gastric, pancreatic, hepatic, pleural, pericardial, peritoneal, intestinal, prostatic, seminal, vaginal secretions, tears, saliva, mucus, bile, blood, lymph, plasma, serum, synovial fluid, cerebrospinal fluid, urine, and interstitial, intracellular, or extracellular fluid.
5. The method of claim 1 , wherein said biocompatible polymer comprises particles having a diameter in the range for 0.1 micron meters to 2 centimeters.
6. The method of claim 1 , wherein said biocompatible polymer is in the form of powder or beads.
7. The method of claim 1 , wherein the sorbent is supplied as slurry, or suspension, or dry powder.
8. The method of claim 1 , wherein said biocompatible polymer is a coated polymer comprising at least one crosslinking agent and at least one dispersing agent;
said dispersing agents such as hydroxyethyl cellulose, hydroxypopyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylamimoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), poly(N-vinylpyrrolidinone), salts of poly(methacrylic acid), and salts of poly(acrylic acid) and mixtures thereof;
said crosslinking agent selected from a group consisting of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital dimethacrylates, pentaerythrital trimethacrylates, pentaerythrital, tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triiacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, divinylformamide and mixtures thereof;
wherein said dispersing agent is chemically bound to said surface of said biocompatible polymer.
9. The method of claim 1 , wherein the cytokine is produced in response to an infection in said patient from E. coli 0157:H7.
10. The method of claim 1 , wherein the cytokine is produced in response to an infection in said patient from Bacillus anthracis (anthrax), influenza virus, smallpox virus, Yersinia pestis (plague), cholera toxin, botulinum toxin, ricin toxin, Salmonella, Escherichia coli, Shigella , or Listeria.
11. The method of claim 1 , wherein the cytokine is produced in response to an infection in said patient from endotoxemia, Ebola virus, Marburg virus, Francisella tularensis (tularemia), or hantavirus.